Events - Pharvaris N.V.

Upcoming Events

Nov 30 - Dec 1, 2026

The British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference 2026

Dec 2, 2026 10:00 AM EST

9th Annual Evercore Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Dec 4 - Dec 6, 2026

The Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) 2026 Congress

Dec 9 - Dec 10, 2026

8th Global Urticaria Forum (GUF) 2026

Past Events

Dec 1 - Dec 2, 2025

2025 BSI Clinical Immunology Professional Network (BSI-CIPN) Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 226.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 329.8 KB

Nov 6 - Nov 10, 2025

American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1 660.2 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results 338.8 KB

Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis 237.9 KB

Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 179.6 KB

Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results 229.3 KB

Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 553.5 KB

Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema 505.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension 523 KB

Oct 24 - Oct 26, 2025

Japanese Society of Allergology (JSA)

Supporting Materials

Deucrictibant vs. Standard of Care in HAE 633.8 KB

Oral Deucrictibant XR Tablet for Prophylaxis of HAE Attacks: CHAPTER-3 Phase 3 Trial Design 888.3 KB

Oct 10 - Oct 12, 2025

2025 HAE International (HAEi) Regional Conference EMEA

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 437 KB

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life and Disease Control in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 551 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 300.3 KB

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 292.2 KB

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 255.5 KB

Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples 563.9 KB

Oct 3 - Oct 5, 2025

Joint XXXVII Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC) National Congress and World Allergy Organization Congress (WAO)

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design 185 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 233.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 167.6 KB

Oct 2 - Oct 4, 2025

Deutscher Allergiekongress (DAK)

Supporting Materials

Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1.8 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 1.5 MB

Oct 1 - Oct 4, 2025

Spanish Society of Allergology and Clinical Immunology (SEAIC)

Supporting Materials

Acquired Angioedema Due to C1-Inhibitor Deficiency: Conceptual Model of Patient Experience and Assessment of Patient-Reported Outcome Measures 334.3 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for the Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1 MB

Durability of Response to a Single Dose of Oral Deucrictibant for the On-Demand Treatment of Hereditary Angioedema Attacks 979.3 KB

Sep 26 - Sep 28, 2025

Consortium of Independent Immunology Clinics (CIIC) Fall 2025 Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study and Post-hoc Analysis on Durability of Response to a Single Dose of Oral Deucrictibant 345.5 KB

Long-Term Safety, Efficacy and Sustained Therapeutic Exposure of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension and Results of a Pharmacokinetics Study in Healthy Volunteers 1.3 MB

Aug 27 - Aug 29, 2025

European Academy of Allergy & Clinical Immunology (EAACI) Hong Kong Allergy School 2025

Supporting Materials

Efficacy and Safety of Oral Deucrictibant for Prophylactic (CHAPTER-3) and for On-Demand (RAPIDe-3) Treatment of Hereditary Angioedema Attacks in Adolescents and Adults: Two Phase 3 Trial Designs 925.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylactic and On-Demand Treatment of Hereditary Angioedema Attacks: Results of the CHAPTER-1 and RAPIDe-2 Extension Trials 1.2 MB

Aug 7 - Aug 9, 2025

Argentine Association of Allergy and Clinical Immunology Congress

Supporting Materials

CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks  1.2 MB

RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 1.6 MB

Pagination

First page
Previous page
…
Page 2
Page 3
Current page 4
Page 5
Page 6
…
Next page
Last page